Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.65 |
| ▸ | CDK8 | P49336 | 3/20 | 0.65 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.65 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.65 |
| ▸ | MET | P08581 | 1/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | RET | P07949 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | LTK | P29376 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.52 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11117497 | 0.87 | ROCK1 (0.60) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11120803 | 0.87 | ROCK1 (0.60) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11115564 | 0.86 | ROCK1 (0.62) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11121730 | 0.86 | PDGFRB (0.62) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11119395 | 0.86 | PDGFRB (0.69) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11119155 | 0.85 | ROCK1 (0.61) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11117079 | 0.85 | PDGFRB (0.61) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11117812 | 0.85 | PDGFRB (0.61) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11117107 | 0.85 | PDGFRB (0.61) | PDGFRBCDK8NTRK3NTRK2AURKB | |
| SCHEMBL11120927 | 0.84 | PDGFRB (0.62) | PDGFRBCDK8NTRK3NTRK2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4397854-A | INCREASE IN MYOCARDIAL CONTRACTILITY | WARNER-LAMBERT COMPANY (US) | 1983-08-09 | — | — | US | claimed |
| EP-2970145-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BROAD INST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014164704-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-0116853-A1 | Pyridazinones, processes for preparing them, therapeutical compositions containing these compounds and their use | BASF Aktiengesellschaft (DE) | 1984-08-29 | — | — | EP | disclosed |
| US-4397854-A | INCREASE IN MYOCARDIAL CONTRACTILITY | WARNER-LAMBERT COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDGFRB 2161/4885CDK8 325/4885NTRK3 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.